Cytomed Therapeutics management commentary says H1 2026 net loss narrows 20.1% to S$ 1.79 million on lower costs and gains on forex and warrant liabilities

• Management commentary from Cytomed Therapeutics outlined a net loss of S$ 1.79 million for the six months ended June 30, 2026, down 20.1%.
• Performance reflected lower other expenses, led by reduced share-based consultancy costs, partly offset by higher investor relations spending.
• Other income fell to S$ 254,719 due to lower interest income and research income.
• Other revenue from private blood banking was S$ 157,289, little changed from the prior-year period.
• Cash and bank balances declined to S$ 1.46 million; financing inflows included S$ 699,600 in a director loan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytomed Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-045045), on September 30, 2026, and is solely responsible for the information contained therein.